Synthetic analogues of the natural molecule teixobactin have exhibited superior efficacy compared to established drugs in combating superbugs like MRSA, according to new research from a team at the University of Liverpool. In the face of rising antimicrobial resistance (AMR), where nearly five million people succumb to antibiotic resistance-associated infections annually, the development of new antibiotics is critical.
Led by Ishwar Singh, senior author on the paper published in the European Journal of Medicinal Chemistry, the research team created 16 different synthetic versions of teixobactin, optimizing key features for enhanced efficacy and safety. The researchers strategically replaced key building blocks with cost-effective alternatives, ensuring the analogues remain effective against a broad spectrum of bacteria.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
According to Dr. Singh, “Teixobactin molecules have the potential to provide new treatment options against multi drug resistant bacterial and biofilm related infections to improve and save lives globally. Our study provides a promising foundation for further research, and opens avenues to explore the application of teixobactin in various health related biofilm contexts, including surgical site infections, implant-related surgeries and cystic fibrosis patients.”